外泌体微RNA在骨恶性肿瘤中的研究进展及展望  

Research progress and prospects of exosomal microRNAs in bone malignancies

作　　者：李林洋 张永博 张玉杰 霍录宽 刘彦宾 LI Linyang;ZHANG Yongbo;ZHANG Yujie;HUO Lukuan;LIU Yanbin(School of Clinical Medicine,Shandong Second Medical University,Weifang,Shandong 261000,P.R.China;Department of Spine Surgery,Liaocheng People’s Hospital,Beijing Jishuitan Hospital Liaocheng Branch,Liaocheng,Shandong 252000,P.R.China)

机构地区：[1]山东第二医科大学临床医学院,山东潍坊261000 [2]聊城市人民医院、北京积水潭医院聊城医院脊柱外科,山东聊城252000

出　　处：《华西医学》2024年第12期1978-1982,共5页West China Medical Journal

基　　金：山东省自然科学基金(ZR2020MH100);山东省中医药科技项目(M-2023214)。

摘　　要：骨恶性肿瘤具有发病率高、预后差、化疗耐药性强等特点。外泌体微RNA可调控肿瘤细胞的增殖、改善化疗耐药性、影响细胞通信和微环境,在骨恶性肿瘤的诊断和治疗中具有巨大潜力。外泌体微RNA因具有稳定性可作为诊断和预后的无创生物标志物,但其大规模应用于临床仍需规范化研究。该文综述了外泌体微RNA在多种骨恶性肿瘤,包括骨肉瘤、软骨肉瘤、尤文肉瘤和纤维肉瘤中的研究进展,旨在为该领域提供新的理论基础和视角。Bone malignancies exhibit the characteristics of high incidence,poor prognosis,and strong chemoresistance.Exosomal microRNAs can regulate the proliferation of bone malignant cells,improve chemoresistance,influence cell communication and the microenvironment,and have significant potential in the diagnosis and treatment of bone malignancies.Due to their stability,exosomal microRNAs can serve as non-invasive biomarkers for diagnosis and prognosis.However,their widespread application in clinical settings requires standardized research.This review summarizes the progress of exosomal microRNA research in various bone malignancies including osteosarcoma,chondrosarcoma,Ewing sarcoma,and fibrosarcoma,to provide new theoretical foundations and perspectives for the field.

关 键 词：外泌体 微RNA 骨恶性肿瘤 耐药性 治疗靶点 

分 类 号：R738.1[医药卫生—肿瘤]